StemSight Overview

  • Year Founded
  • 2021

Year Founded

  • Status
  • Private

  • Employees
  • 10

Employees

  • Latest Deal Type
  • Early Stage VC

  • Latest Deal Amount
  • $351K

  • Investors
  • 13

StemSight General Information

Description

Developer of an off-the-shelf cell therapy platform designed to treat blindness. The company's platform treats cells based on induced pluripotent stem cells (iPSCs) and biomaterials, and it aims to enter the market with a first-in-class therapy for a rare disease, limbal stem cell deficiency, later expanding to major forms of corneal blindness, enabling patients with corneal blindness to regain their vision.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Finn-Medi 5, 6th floor
  • Biokatu 12
  • 33520 Tampere
  • Finland
+358 050
Primary Industry
Biotechnology
Corporate Office
  • Finn-Medi 5, 6th floor
  • Biokatu 12
  • 33520 Tampere
  • Finland
+358 050

StemSight Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

StemSight Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
14. Early Stage VC 30-Apr-2026 $351K Completed Startup
13. Accelerator/Incubator 12-Feb-2026 Completed Startup
12. Grant 01-Jan-2025 Completed Startup
11. Accelerator/Incubator 01-Jan-2025 Completed Pre-Clinical Trials
10. Early Stage VC 22-Nov-2024 Completed Pre-Clinical Trials
9. Accelerator/Incubator 01-Jan-2024 Completed Pre-Clinical Trials
8. Grant 21-Jun-2023 Completed Startup
7. Accelerator/Incubator 09-Jun-2023 Completed Startup
6. Accelerator/Incubator 01-Apr-2023 $80.4K $672K Completed Startup
5. Grant 15-Mar-2022 $55.7K $591K Completed Startup
To view StemSight’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

StemSight Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of an off-the-shelf cell therapy platform designed to treat blindness. The company's platform treats cells bas
Biotechnology
Tampere, Finland
10 As of 2026

Tokyo, Japan
 

Seattle, WA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

StemSight Competitors (3)

One of StemSight’s 3 competitors is Cellusion, a Venture Capital-Backed company based in Tokyo, Japan.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Cellusion Venture Capital-Backed Tokyo, Japan
Aurion Biotech Formerly VC-backed Seattle, WA
Claris Bio Venture Capital-Backed Half Moon Bay, CA
You’re viewing 3 of 3 competitors. Get the full list »

StemSight Patents

StemSight Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
CA-3192264-A1 Method for differentiating corneal endothelial cell-like cells from pluripotent stem cells Pending 03-Sep-2020
EP-4208539-A1 Method for differentiating corneal endothelial cell-like cells from pluripotent stem cells Pending 03-Sep-2020
US-20230392116-A1 Method for differentiating corneal endothelial cell-like cells from pluripotent stem cells Pending 03-Sep-2020
WO-2022049328-A1 Method for differentiating corneal endothelial cell-like cells from pluripotent stem cells Inactive 03-Sep-2020
JP-2026067912-A Method for obtaining or maintaining abcg2 positive limbal stem cells Pending 01-Apr-2019 C12N5/0621
To view StemSight’s complete patent history, request access »

StemSight Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

StemSight Investors (13)

Investor Name Investor Type Holding Investor Since Participating Rounds
Japan External Trade Organization Accelerator/Incubator
Biothom Venture Capital Minority
Stephen Industries Venture Capital Minority
Nordic Mentor Network For Entrepreneurship Accelerator/Incubator Minority
European Commission Government
You’re viewing 5 of 13 investors. Get the full list »

StemSight FAQs

  • When was StemSight founded?

    StemSight was founded in 2021.

  • Where is StemSight headquartered?

    StemSight is headquartered in Tampere, Finland.

  • What is the size of StemSight?

    StemSight has 10 total employees.

  • What industry is StemSight in?

    StemSight’s primary industry is Biotechnology.

  • Is StemSight a private or public company?

    StemSight is a Private company.

  • What is the current valuation of StemSight?

    The current valuation of StemSight is .

  • What is StemSight’s current revenue?

    The current revenue for StemSight is .

  • How much funding has StemSight raised over time?

    StemSight has raised $3.92M.

  • Who are StemSight’s investors?

    Japan External Trade Organization, Biothom, Stephen Industries, Nordic Mentor Network For Entrepreneurship, and European Commission are 5 of 13 investors who have invested in StemSight.

  • Who are StemSight’s competitors?

    Cellusion, Aurion Biotech, and Claris Bio are competitors of StemSight.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process